Current Liabilities
Operating Lease Liability Payments - 2024 (Lessee)
Neurocrine Biosciences Operating Lease Liability Payments - 2024 (Lessee) increased by 0.2% to $59.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 0.8%, from $59.20M to $59.70M. This increase may warrant attention — for this metric, lower values are generally preferred.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryLiquidity
SignalLower is better
VolatilityStable
First reportedQ2 2020
Last reportedQ1 2026May 5, 2026
How to read this metric
Higher payments indicate increased short-term cash requirements for maintaining the current operational footprint.
Detailed definition
This represents the total cash payments expected to be made for operating leases during the 2024 fiscal year. It is a fo...
Peer comparison
Standard disclosure; peers provide this to assist in cash flow modeling and liquidity assessment.
Metric ID:
lease_liability_payments_2024_lesseeHistorical Data
15 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $17.50M | $17.50M | $17.40M | $17.40M | $17.40M | $15.90M | $17.00M | $17.00M | $34.00M | $34.90M | $34.90M | $59.20M | $59.20M | $59.60M | $59.70M |
| QoQ Change | — | +0.0% | -0.6% | +0.0% | +0.0% | -8.6% | +6.9% | +0.0% | +100.0% | +2.6% | +0.0% | +69.6% | +0.0% | +0.7% | +0.2% |
| YoY Change | — | — | — | -0.6% | -0.6% | -8.6% | -2.3% | -2.3% | +113.8% | +105.3% | +105.3% | +74.1% | +69.6% | +70.8% | +0.8% |
Range$15.90M – $59.70M
CAGR+42.0%
Avg YoY Growth+43.8%
Median YoY Growth+35.2%
Current Streak9 quarters growth
Operating Lease Liability Payments - 2024 (Lessee) at Other Companies
Frequently Asked Questions
- What is Neurocrine Biosciences's operating lease liability payments - 2024 (lessee)?
- Neurocrine Biosciences (NBIX) reported operating lease liability payments - 2024 (lessee) of $59.70M in Q1 2026.
- How has Neurocrine Biosciences's operating lease liability payments - 2024 (lessee) changed year-over-year?
- Neurocrine Biosciences's operating lease liability payments - 2024 (lessee) increased by 0.8% year-over-year, from $59.20M to $59.70M.
- What does operating lease liability payments - 2024 (lessee) mean?
- The total cash payments due for operating leases in the 2024 calendar year.